The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60.

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

Compared with flu vaccine recipients, those given the RSV or shingles vaccine had 18% to 37% lower odds of receiving a ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

The CDC's newly reconstituted Advisory Committee on Immunization Practices (ACIP) voted 5-2 in support of infants younger ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

The U.S. Food and Drug Administration has approved three vaccines for RSV — GSK's Arexvy, Moderna's mRESVIA and Pfizer's ...

The U.S. Centers for Disease Control and Prevention (CDC) has accepted recommendations from an advisory panel that endorsed ...